Arbutus Announces Initiation of Patient Dosing in the TKM-PLK1 HCC Expansion Cohort

Arbutus Biopharma Corporation

, an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced the initiation of dosing in the 20 subject expansion cohort of the TKM-PLK1 hepatocellular carcinoma (HCC) Phase IIa clinical study. This study is designed to evaluate TKM-PLK1's safety and efficacy in treating HCC patients. "This is an important milestone for the company as we continue the execution of our strategy to progress our HBV-related clinical candidates," said Dr. Mark J. Murray, Arbutus' President and CEO. "HCC is one of the most common cancers in the world, primarily caused by an underlying chronic HBV infection. The goal of this study is to further evaluate the anti-tumor efficacy of TKM-PLK1 in treating HCC patients."